New research signposts a new, less invasive approach to identify killer T lymphocytes in patients with gastrointestinal tumors with low mutational burden who are refractory to approved immune-based treatments.
Read moreA new study of tumor samples from people with the rare genetic syndrome neurofibromatosis type 1 (NF1) has uncovered novel molecular clues about which tumors are most likely to be aggressive in those with NF1. According to the researchers, the clues could advance the search for more customized and relevant treatments that spare patients exposure to treatments unlikely to work.
Read moreThe Cancer Atlas, 3rd edition, a comprehensive global overview of cancer around the globe, concludes that progress in the fight against cancer is not only possible, but achievable.
Read moreA chemical that has improved surgeries for brain cancer by making tumor cells fluorescent may also help doctors safely diagnose the disease and monitor its response to treatment.
Read moreResearchers report that Acceptance and Commitment Therapy (ACT) shows significant promise for treating fear of cancer recurrence in women who have survived breast cancer. Fear that cancer may come back or progress is especially common in breast cancer survivors, with up to 70% reporting that the fear affects their daily life.
Read moreBioengineers are a step closer to making CAR T-cell therapy safer, more precise and easy to control. They developed a system that allows them to select where and when CAR T cells get turned on so that they destroy cancer cells without harming normal cells. The system requires two 'keys' — the drug Tamoxifen and blue light — to activate CAR T cells to bind to their targets.
Read moreThe aim of immunotherapies is to enable the immune system once again to fight cancer on its own. Drugs known as checkpoint inhibitors are already in clinical use for this purpose. However, they are only effective in about one third of patients. Based on analysis of human tissue samples, a team has now discovered one reason why this is so: an inactive receptor in cancer cells prevents the drugs from reactivating the immune system.
Read moreResearchers decipher assembly of glutamate receptors and its importance for memory formation.
Read moreScientists have developed a new and more accurate method to identify the molecular signs of cancer likely to be presented to helper T cells, which stimulate and orchestrate the immune response to tumors and infectious agents.
Read moreA multi-institutional team has brought attention to genomic structural variation as a previously unappreciated mechanism involved in altering DNA methylation, a form of gene control, in human cancers.
Read more